Mubadala Bio Introduces Eight Locally Produced Essential Medications To Enhance UAE Drug Security

Mubadala Bio has introduced eight essential medicines in the UAE, marking a significant step in enhancing national drug security. This initiative aligns with the company's goal to improve health outcomes for patients in the UAE and the broader region. The introduction of these medicines underscores Mubadala Bio's commitment to making the UAE a regional hub for life sciences.

The newly launched medicines are now produced locally at Mubadala Bio’s facilities, including Gulf Inject, Wellpharma, and Bioventure Healthcare. These facilities ensure a steady supply of critical medical therapies, addressing the increasing demand for essential treatments. The local production strengthens the nation's capacity to maintain reliable access to vital medical supplies.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio, stated, "As a national champion, Mubadala Bio was launched to strengthen the UAE’s life sciences sector and to enable local production of essential medications. With the launch of these products, Mubadala Bio is delivering on this commitment, and is ensuring a continuous and reliable supply of key medical therapies locally."

Dr. Essam Mohamed, CEO of Mubadala Bio, expressed satisfaction with introducing new locally produced medications that benefit healthcare providers and patients across the UAE. He noted that these efforts demonstrate their long-term dedication to bolstering the country's life sciences sector and enhancing local manufacturing capabilities.

The medicines include Rivaroxaban for preventing blood clots, Linezolid for treating drug-resistant infections, Sugammadex for anesthesia recovery post-surgery, Fluconazole for severe fungal infections, Pantoprazole for reducing stomach acid, Ondansetron for preventing nausea from cancer treatment, Bupivacaine as a long-acting anesthetic for pain control, and Sodium Chloride Inhalation Solution for clearing airways.

Commitment to Global Leadership

Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, highlighted that these launches demonstrate how Mubadala Bio is not only addressing current needs but also shaping the future of the life sciences industry in the UAE and beyond. He emphasized their dedication to achieving transformative health outcomes and becoming a global leader in their field.

Mubadala Bio operates 10 pharmaceutical assets across Asia, Africa, and Europe — including six in the UAE — with capabilities to produce various dosage forms like tablets, capsules, IV injectables as well as eye and ear drops. The company distributes over 10,000 products to more than 100 countries.

This strategic move by Mubadala Bio reflects its ongoing efforts to support sustainable growth in the UAE's knowledge-based economy while improving access to essential medicines throughout the region.

With inputs from WAM